drugset
drugset / Trial / NCT04208997

Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

NCT04208997 ↗

Phase 3 Terminated 5 enrolled Vanderbilt University Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators aim to study if patients that undergo catheter ablation for ventricular tachycardia benefit from continuation of Vaughan-Williams class III antiarrhythmic drugs for 3 months after their ablation.

Timeline

Start
2019-12-19
Primary completion
2021-06-30
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amiodarone Small molecule — —
Subject sotalol Small molecule — —

Indications

ventricular tachycardia